The long-awaited Canadian approval of lecanemab has shifted physicians’ approach to Alzheimer’s disease, addressing previous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback